Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study
2,834 individuals in Geneva, Switzerland were enrolled in the study between April 6-May 8, 2020 to assess seroprevalence for SARS-CoV-2 anti-S1 IgG antibodies by ELISA.
Demographics
- 52.6% women
- Age: 5-9 (4.4%), 10-19 (12%), 20-49 (39.6%), 50-64 (30.6%), 65+ (13.3%)
- 1339 different households: 529 solo participants, 435 with one additional household member, 178 with two additional members, and 197 with three or more
0
1
Contributors are:
Who are from:
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study
Hospital-Wide SARS-CoV-2 Antibody Screening in 3056 Staff in a Tertiary Center in Belgium
Introduction for Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections
Summary for Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study
Antibody Testing in Germany
Antibody dynamics to SARS-CoV-2 in Asymptomatic and Mild COVID-19 patients
SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months
Prevalence of IgG antibodies to SARS-CoV-2 in Wuhan–implications for the ability to produce long-lasting protective antibodies against SARS-CoV-2
Diagnostic Tool for Coronavirus Being Developed by University of Warwick
Saliva could be an alternative fluid to test COVID-19 antibodies
Seroprevalence of anti-SARS-CoV-2 spike protein antibodies in the New York Metropolitan Area
Learn After
Methods: Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study
Results: Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study
Discussion: Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study